SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

NIKE, Inc. engages in the design, development, marketing, and sale of athletic footwear, apparel, accessories, equipment, and services. It operates through the following segments: North America, Europe, Middle East, and Africa (EMEA), Greater China, Asia Pacific and Latin America (APLA), Global Brand Divisions, Converse, and Corporate. The North America, EMEA, Greater China, and APLA segments refer to the design, development, marketing, and selling of athletic footwear, apparel, and equipment. The Global Brand Divisions segment represents its NIKE Brand licensing businesses. The Converse segment designs, markets, licenses, and sells casual sneakers, apparel, and accessories. The Corporate segment is composed of unallocated general and administrative expenses. The company was founded by William Jay Bowerman and Philip Hampson Knight on January 25, 1964 and is headquartered in Beaverton, OR.

Nike, Inc. - Ordinary Shares - Class B

Nike Inc

Nike is experiencing intense volatility as shareholders push for leadership changes and express frustration over slumping sales, high inventory levels, and a perceived disconnection from modern consumer trends. The market is deeply divided ahead of its earnings release, with a significant cohort of traders actively shorting the stock, while others view its recent descent to multi-year lows as a potential, though highly risky, entry point for a long-term turnaround.

RH operates as a holding company which operates the business through its subsidiary Restoration Hardware, Inc. It offers furniture, lighting, textiles, bath ware, decor, outdoor and garden, as well as baby and child products. The company operates an integrated business with multiple channels of distribution including galleries, source books and websites. The company was founded by Stephen J. Gordon in 1980 and is headquartered in Corte Madera, CA.

RH - Ordinary Shares - Class A

Restoration Hardware

Restoration Hardware is experiencing significant volatility as investors weigh the company's exposure to ongoing tariff risks against its ambitious international expansion and long-term luxury strategy. The community remains deeply divided, with some traders betting on a short squeeze or a valuation recovery, while others express skepticism over the firm's leadership and the sustainability of its high-end furniture pricing in a strained economic environment.

BRC Group Holdings, Inc. engages in the provision of financial services and solutions to the capital raising and financial advisory needs of public and private firms. It operates through the following segments: Capital Markets, Wealth Management, Financial Consulting, Auction and Liquidation, Communications, and Consumer. The Capital Markets segment provides investment banking, corporate finance, research, wealth management, and sales and trading services to corporate, institutional, and high net worth clients. The Wealth Management segment offers retail brokerage, investment management, and insurance, and tax preparation services. The Financial Consulting segment focuses on a variety of specialized advisory services spanning bankruptcy, restructuring, turnaround management, forensic accounting, crisis and litigation support, appraisal and valuation, real estate, and operations management. The Auction and Liquidation segment deals with retail liquidation services. The Communications segment is composed of a portfolio of companies acquired for attractive risk-adjusted investment return characteristics. The Consumer segment includes Targus and the Brands investment portfolio. The company was founded in 1973 and is headquartered in Los Angeles, CA.

BRC Group Holdings Inc.

B. Riley Financial Inc

B. Riley Financial is trending as investors gear up for the upcoming 10-K filing and earnings report, with the community closely tracking the company's aggressive debt reduction efforts and the performance of key holdings like Applied Digital and BW. Bullish sentiment remains high as retail participants anticipate a potential valuation re-rating driven by balance sheet improvements and a possible short squeeze.

Omeros Corp. operates as a biopharmaceutical company. The firm engages in the discovery, development, and commercializing of both small-molecule and protein therapeutics for large market. It also offers orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. The company was founded by Gregory A. Demopulos and Pamela Pierce Palmer on June 16, 1994 and is headquartered in Seattle, WA.

Omeros Corporation

Omeros Corp

Omeros Corp is trending as investors monitor the early commercial rollout of Yartemlea and anticipate further clarity on revenue ramp and European regulatory progress. The community remains focused on potential milestone payments from the partnership with Novo Nordisk and the company's long-term potential as a commercial-stage biotech, despite current frustration over recent share price volatility and limited official guidance.

Dave & Buster's Entertainment, Inc. engages in the ownership and operation of entertainment and dining venues under the name Dave & Buster's. It offers a full menu of entrées and appetizers, a selection of alcoholic and non-alcoholic beverages, and an assortment of entertainment attractions centered around playing games and watching live sports and other televised events. The company was founded by David O. Corriveau and James W. Corley in 1982 and is headquartered in Coppell, TX.

Dave & Buster`s Entertainment Inc

Dave & Buster's Entertainment

Dave & Buster's is currently a focal point for investors due to its high short interest and speculative potential for a short squeeze, despite ongoing concerns about its business model and the impact of discretionary spending shifts. The community is actively debating the company's turnaround strategy under new leadership while weighing the risks of its significant debt levels against the possibility of institutional share accumulation.

"What's Updog?" is a Community Led token.

UpDog

The UpDog community is driving significant engagement through a coordinated social campaign to increase visibility and brand awareness. Discussions are largely centered around community building, frequent meme-style interaction, and encouraging new participants to join their ecosystem.

Tema ETF Trust - Tema Space Innovators ETF

Investors are closely tracking NASA for its strategic exposure to the burgeoning space economy, with particular interest in its significant holdings in companies connected to private aerospace ventures. The community is actively discussing the ETF's portfolio composition and its potential to capture long-term growth within the specialized space innovation sector.

Oric Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in the development of cancer treatments that address mechanisms of therapeutic resistance. It specializes in hormone-dependent cancers, key tumor dependencies, and precision oncology. The company was founded by Charles L. Sawyers, Richard A. Heyman, and Scott Lowe in 2014 and is headquartered in South San Francisco, CA.

ORIC Pharmaceuticals Inc

ORIC Pharmaceuticals is trending following positive preliminary efficacy and safety data from its Phase 1b trial of ORIC-944 in combination with androgen receptor inhibitors for prostate cancer. Investors are actively discussing the significance of the company's recent capital raise, its partnership with Pfizer, and the potential for a short squeeze given the high short interest.

POET Technologies, Inc. engages in the designing, developing, manufacturing and sale of opto-electronic solutions for the sensing, data communications and telecommunications markets. It developed POET Optical Interposer platform, which allows the integration of electronic and photonic devices into a single multi-chip module. The company was founded on November 14, 1985 and is headquartered in Toronto, Canada.

POET Technologies Inc

POET Technologies is seeing intense community debate as investors weigh the company's transition from R&D to production-scale manufacturing, with recent chatter heavily focused on interpreting potential indirect ties to major industry players like NVIDIA and Marvell. While bulls emphasize the strategic long-term value of their optical interposer technology and validated partnerships, bears remain vocal about the lack of significant near-term revenue and the ongoing dilution risk that has fueled skepticism regarding management's execution.

SPDR S&P 500 ETF TRUST - Units of undivided interest in SPDR Trust Series 1

The S&P 500 ETF (SPY) saw a major rally driven by optimism surrounding potential de-escalation in Iran following statements from the White House, fueling a powerful short-covering squeeze. While bullish sentiment has surged, the community remains deeply divided, with many traders questioning the validity of the news and bracing for a potential rug pull as they closely watch geopolitical headlines and energy prices.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Milestone Pharmaceuticals Inc. (NASDAQ:MIST) Receives Consensus Recommendation of "Hold" from Brokerages

Milestone Pharmaceuticals Inc. (NASDAQ:MIST - Get Free Report) has been assigned an average recommendation of "Hold" from the six ratings firms that are currently covering the company, Marketbeat.com...

Milestone Pharmaceuticals (NASDAQ:MIST) Upgraded by Wall Street Zen to "Hold" Rating

Wall Street Zen upgraded Milestone Pharmaceuticals from a "sell" rating to a "hold" rating in a report on Saturday...

Milestone Pharmaceuticals (MIST) Projected to Post Earnings on Tuesday

Milestone Pharmaceuticals (NASDAQ:MIST) will be releasing its Q4 2025 earnings before the market opens on Tuesday, March 31. (View Earnings Report at...

Equities Analysts Issue Forecasts for MIST FY2028 Earnings

Milestone Pharmaceuticals Inc. (NASDAQ:MIST - Free Report) - Equities researchers at HC Wainwright lowered their FY2028 earnings per share estimates for shares of Milestone Pharmaceuticals in a research report issued on Friday, March 20th. HC Wainwright analyst B. Folkes now forecasts that the compa...

Milestone Pharmaceuticals (NASDAQ:MIST) Posts Quarterly Earnings Results, Beats Estimates By $0.02 EPS

Milestone Pharmaceuticals (NASDAQ:MIST - Get Free Report) released its quarterly earnings results on Friday. The company reported ($0.16) earnings per share for the quarter, topping the consensus estimate of ($0.18) by $0.02. The firm had revenue of $1.44 million during the quarter, compared to the...

Milestone Pharmaceuticals Q4 Earnings Call Highlights

Milestone Pharmaceuticals (NASDAQ:MIST) executives highlighted the company's transition to commercialization during a year-end 2025 update call, following the U.S. Food and Drug Administration's...

Milestone Pharmaceuticals Gears Up For Q4 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts

Earnings report for Milestone Pharmaceuticals Inc. (MIST) expected on March 19. Analysts predict 16 cents per share on $1.20M revenue.read more...

Boxer Capital Management LLC Invests $1.33 Million in Milestone Pharmaceuticals Inc. $MIST

Boxer Capital Management LLC purchased a new stake in shares of Milestone Pharmaceuticals Inc. (NASDAQ:MIST - Free Report) during the third quarter, according to its most recent Form 13F filing with...

Milestone Pharmaceuticals Inc. $MIST Shares Purchased by Propel Bio Management LLC

Propel Bio Management LLC boosted its holdings in shares of Milestone Pharmaceuticals Inc. (NASDAQ:MIST - Free Report) by 186.1% during the 3rd quarter, according to its most recent filing with the...

Milestone Pharmaceuticals Inc. (NASDAQ:MIST) Receives Average Rating of "Hold" from Brokerages

Shares of Milestone Pharmaceuticals Inc. (NASDAQ:MIST - Get Free Report) have received a consensus recommendation of "Hold" from the six analysts that are presently covering the company, MarketBeat...

Milestone Pharmaceuticals, Inc. engages in the development and commercialization of cardiovascular medicines. Its lead product candidate etripamil, is a novel, potent and short-acting calcium channel blocker that is designed as a rapid-onset nasal spray to be self-administered by patients. It develops etripamil to treat paroxysmal supraventricular tachycardia, atrial fibrillation, rapid ventricular rate, and other cardiovascular indications. The company was founded by Philippe Douville and Philippe Lamarre in 2003 and is headquartered in Montreal, Canada.

Milestone Pharmaceuticals Inc

iShares Dynamic Equity Active ETF ($BDYN)

Grayscale Bitcoin Trust ETF ($GBTC)

Destiny Tech100 Inc ($DXYZ)

Global X Defense Tech ETF ($SHLD)

The Modern Portfolio Builder. This award honors the fund that makes long-term investing easier, cheaper, or more effective for people who want to "set it and forget it."

Fiscal Period	Estimated	Reported	Surprise	Result
Q1 '26	$0.23	--	--	N/A
Q4 '25	-$0.16	-$0.16	0.12%	BEAT
Q3 '25	-$0.16	-$0.12	26.83%	BEAT
Q2 '25	-$0.18	-$0.20	-12.68%	MISSED
Q1 '25	-$0.19	-$0.31	-67.57%	MISSED

MIST
Milestone Pharmaceuticals Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest Earnings Results: Q4 '25

Historical Earnings

Latest MIST News

MISTMilestone Pharmaceuticals Inc